IQVIA Reports Strong Q3 2026 Results with Record Clinical Bookings and Raised Guidance
IQVIA (IQV) reported robust third-quarter 2026 financial results, highlighted by accelerating revenue growth and record clinical bookings. The contract research organization saw net new clinical bookings reach $3.2 billion for the quarter, contributing to a 14% year-over-year increase in trailing 12-month bookings to $11.7 billion. This momentum is driven largely by recovering funding among emerging biopharma companies. The company is successfully leveraging artificial intelligence to deepen client integration and shorten clinical trial timelines, which has bolstered both customer retention and subscription revenue. Despite headwinds from increased pass-through costs, IQVIA's focus on internal automation and operational efficiency has allowed profit margins to expand. Consequently, management has raised its full-year 2026 revenue guidance to at least $17.35 billion.
Tickers: $IQV
Topics: artificial intelligence biotechnology clinical trials financial guidance